enteroviru
caus
fatal
enceph
young
children
howev
effect
antivir
drug
avail
infect
patient
ribavirin
current
use
treatment
sever
rna
viru
infect
clinic
efficaci
evalu
vitro
result
show
ribavirin
effect
reduc
viral
yield
ic
gml
virusinduc
cytopath
effect
human
mous
cell
line
vivo
result
show
ribavirin
reduc
mortal
morbid
subsequ
paralysi
sequela
infect
mice
decreas
viral
load
tissu
thu
ribavirin
could
potenti
drug
enteroviru
member
famili
picornavirida
infect
human
fecalor
rout
induc
herpangina
viremia
handfootandmouth
diseas
initi
ill
selflimit
sometim
follow
fatal
neurolog
symptom
asept
mening
brainstem
enceph
encephalomyel
acut
flaccid
paralysi
similar
paralyt
poliomyel
particularli
infant
young
children
subsequ
survivor
sever
case
left
longterm
neurolog
sequela
delay
neurodevelop
reduc
cognit
function
outbreak
report
period
throughout
world
largest
sever
outbreak
occur
taiwan
case
herpangina
handfootandmouth
diseas
case
neurolog
cardiopulmonari
complic
death
report
sinc
infect
becom
endem
taiwan
caus
death
per
year
current
effect
antivir
drug
avail
treat
patient
infect
support
care
intraven
immunoglobulin
avail
sever
case
therapeut
efficaci
intraven
immunoglobulin
seem
limit
among
antivir
compound
pleconaril
shown
inhibit
picornavirus
includ
coxsackieviru
rhinoviru
fail
show
protect
effect
patient
reduc
cytopath
effect
cpe
cell
induc
isol
patient
outbreak
taiwan
date
pyridyl
imidazolidinon
deriv
compound
promis
activ
vitro
howev
take
year
new
compound
approv
use
patient
ribavirin
nucleosid
analogu
broadspectrum
antivir
activ
varieti
virus
coxsackieviru
echoviru
among
picornavirus
current
use
treat
patient
infect
hepat
c
viru
hcv
respiratori
syncyti
viru
also
shown
reduc
sever
diseas
patient
enceph
induc
nipah
viru
la
cross
viru
measl
viru
patient
hemorrhag
fever
induc
lassa
fever
viru
hantaviru
addit
recommend
clinic
trial
patient
enceph
induc
west
nile
viru
junin
viru
rift
valley
fever
viru
thu
efficaci
ribavirin
evalu
present
studi
result
show
ribavirin
reduc
replic
vitro
vivo
method
human
muscular
rhabdomyosarcoma
rd
neuron
sknsh
mous
neuron
cell
line
maintain
medium
accord
instruct
american
type
cultur
collect
strain
genbank
access
number
isol
patient
encephalomyel
taiwan
propag
titrat
rd
cell
use
infect
human
cell
line
pass
mice
time
obtain
mouseadapt
strain
pass
mice
time
laboratori
design
strain
propag
titrat
rd
cell
use
infect
cell
mice
antivir
assay
rd
sknsh
cell
infect
pfu
cell
infect
pfu
infect
cell
cultur
medium
without
variou
concentr
ribavirin
mp
biomed
h
infect
infect
rd
sknsh
cell
harvest
h
infect
respect
determin
viral
yield
plaqu
assay
rd
cell
determin
whether
ribavirin
reduc
virusinduc
cpe
sknsh
cell
mockinfect
infect
pfu
cultur
medium
without
ribavirin
gml
observ
microscop
photomicrograph
obtain
h
infect
mous
experi
protocol
mous
protect
assay
approv
laboratori
anim
committe
nation
cheng
kung
univers
test
efficaci
ribavirin
vivo
icr
mice
charl
river
laboratori
infect
pfu
intraperiton
inocul
infect
mice
given
intraperiton
inject
pb
ribavirin
mgkg
daili
day
start
h
infect
infect
mice
monitor
daili
day
sign
diseas
surviv
clinic
score
grade
follow
healthi
ruffl
hair
weak
hind
limb
paralysi
singl
hind
limb
paralysi
hind
limb
death
separ
experi
brain
spinal
cord
infect
mice
treat
ribavirin
pb
collect
day
infect
brain
stem
ponsmedulla
region
dissect
brain
sampl
frozen
homogen
frozen
frozen
sampl
thaw
sonic
viral
titer
sampl
determin
plaqu
assay
rd
cell
result
efficaci
ribavirin
first
test
vitro
use
human
muscular
rd
neuron
sknsh
cell
line
infect
clinic
isol
strain
tainan
mous
neuron
cell
line
infect
mouseadapt
strain
deriv
infect
cell
treat
without
variou
concentr
ribavirin
h
infect
harvest
determin
viral
titer
h
infect
viral
titer
rd
sknsh
cell
cultur
without
ribavirin
treatment
reach
pfucultur
respect
condit
ribavirin
abl
reduc
viral
yield
rd
sknsh
cell
dosedepend
manner
figur
demonstr
inhibit
replic
ribavirin
phenomenon
specif
human
mous
cell
particular
cell
type
addit
experi
show
ribavirin
significantli
affect
prolifer
sknsh
cell
littl
toxic
cell
data
shown
figur
ribavirin
effect
inhibit
replic
infect
cell
investig
whether
could
reduc
viru
induc
cpe
infect
sknsh
cell
treat
ribavirin
cell
develop
cpe
h
infect
figur
howev
monolay
infect
cell
treat
gml
ribavirin
remain
intact
mockinfect
cell
data
indic
ribavirin
prevent
virusinduc
cpe
antivir
protect
effect
ribavirin
test
vivo
assess
abil
reduc
mortal
morbid
mice
mice
intraperiton
infect
treat
ribavirin
mgkg
daili
infect
mice
given
pb
develop
hind
limb
paralysi
sign
enceph
manifest
hunch
postur
lethargi
ataxia
anorexia
mice
surviv
figur
infect
mice
treat
ribavirin
show
mark
reduct
mortal
surviv
rate
significantli
higher
pbstreat
mice
p
logrank
test
ribavirintr
mice
show
obviou
symptom
day
infect
wherea
pbstreat
mice
began
develop
paralysi
hind
limb
figur
hind
limb
ribavirintr
mice
slightli
paralyz
sever
significantli
less
pbstreat
mice
day
day
infect
p
wilcoxon
test
thu
ribavirin
treatment
significantli
reduc
mortal
morbid
subsequ
paralysi
sequela
infect
mice
shown
brain
stem
spinal
cord
main
target
sever
case
human
infect
previou
studi
show
high
level
viru
detect
mous
central
nervou
system
day
infect
accordingli
next
investig
viral
load
mous
central
nervou
system
day
infect
data
show
ribavirin
treatment
reduc
viral
load
brain
without
brainstem
region
brain
stem
spinal
cord
mice
figur
addit
experi
show
viru
harvest
tissu
mice
receiv
ribavirin
treatment
still
sensit
ribavirin
treatment
data
shown
discuss
first
report
ribavirin
current
use
treat
sever
rna
viru
infect
patient
antivir
activ
vitro
particularli
vivo
reduc
viral
load
tissu
mortal
morbid
acut
infect
subsequ
sequela
infect
mice
find
particularli
import
effect
antivir
drug
current
avail
prevent
treatment
control
fatal
infect
human
vitro
experi
show
direct
action
ribavirin
human
mous
cell
line
ic
ribavirin
gml
moll
rd
sknsh
cell
lower
found
neurotrop
virus
nipah
viru
west
nile
viru
japanes
enceph
viru
ic
valu
gml
respect
previou
studi
show
mgkg
ribavirin
daili
reduc
mortal
rat
enceph
induc
junin
viru
rhesu
monkey
enceph
induc
rift
valley
fever
viru
mice
myocard
induc
coxsackieviru
basi
studi
mgkg
ribavirin
chosen
treat
mice
dose
show
protect
effect
studi
ribavirin
given
infect
mice
virem
phase
data
shown
studi
need
test
efficaci
ribavirin
therapi
begin
later
diseas
cours
mice
nipah
viru
despit
ic
ribavirin
higher
fact
drug
fail
prevent
death
infect
hamster
ribavirin
treatment
significantli
reduc
mortal
patient
enceph
without
induc
advers
effect
anemia
jaundic
teratogen
effect
commonli
associ
regimen
oral
ribavirin
start
load
dose
mg
daili
regimen
intraven
ribavirin
start
load
dose
mgkg
daili
regimen
plasma
concentr
ribavirin
gml
compar
found
hcvinfect
patient
treat
drug
concentr
ribavirin
cerebrospin
fluid
plasma
human
interestingli
ic
ribavirin
nipah
viru
time
higher
clinic
achiev
concentr
plasma
cerebrospin
fluid
hcv
ic
ribavirin
moll
gml
time
higher
plasma
concentr
fact
ic
ribavirin
almost
virus
drug
show
therapeut
efficaci
patientsinclud
measl
viru
respiratori
syncyti
viru
la
cross
viru
hantaviru
viru
lassa
viru
much
higher
plasma
concentr
evid
ribavirin
inhibit
virus
effici
vivo
vitro
present
studi
found
ic
ribavirin
lower
nipah
viru
importantli
unlik
nipah
viru
ribavirin
protect
mice
infect
reduc
viral
load
tissu
addit
dose
ribavirin
effect
protect
mice
infect
close
initi
dose
drug
use
intraven
improv
condit
patient
enceph
induc
nipah
viru
collect
data
demonstr
ribavirin
could
potenti
drug
previou
studi
show
type
interferon
also
reduc
mortal
mice
altern
combin
ribavirin
interferon
synergist
effect
use
standard
therapi
hcvinfect
patient
could
consid
treatment
potenti
fatal
infect
